PRODUCT MONOGRAPH

**DITROPA XL®**

oxybutynin chloride
Extended-release Tablets, USP
5 mg and 10 mg

Anticholinergic/Antispasmodic Agent

Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9

www.janssen.com/canada

Date of Preparation: January 30, 2002
Date of Revision: August 20, 2018

Submission Control No: 216720

All trademarks used under license.

© 2018 Janssen Inc.
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3
  SUMMARY PRODUCT INFORMATION ........................................................................3
  INDICATIONS AND CLINICAL USE ........................................................................3
  CONTRAINDICATIONS ................................................................................................3
  WARNINGS AND PRECAUTIONS ..............................................................................4
  ADVERSE REACTIONS ...............................................................................................6
  DRUG INTERACTIONS ..............................................................................................10
  DOSAGE AND ADMINISTRATION ..........................................................................11
  OVERDOSAGE ........................................................................................................12
  ACTION AND CLINICAL PHARMACOLOGY .........................................................12
  STORAGE AND STABILITY ....................................................................................14
  DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................14

PART II: SCIENTIFIC INFORMATION ........................................................................16
  PHARMACEUTICAL INFORMATION ......................................................................16
  CLINICAL TRIALS ..................................................................................................16
  DETAILED PHARMACOLOGY ................................................................................18
  TOXICOLOGY .........................................................................................................19
  REFERENCES .........................................................................................................22

PART III: CONSUMER INFORMATION ......................................................................24
PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Extended-release tablet, 5 mg and 10 mg</td>
<td>lactose For a complete listing of nonmedicinal ingredients, see DOSAGE FORMS, COMPOSITION AND PACKAGING section.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

DITROPA XL® (oxybutynin chloride) is indicated for the relief of the symptoms of urge incontinence, urgency and frequency in patients with overactive bladder (U-UI).

Geriatrics (> 65 years of age): The safety and efficacy of DITROPA XL® is similar in patients younger or older than 65 years.

Pediatrics (< 18 years of age): The safety and efficacy of DITROPA XL® in children have not been established.

CONTRAINDICATIONS

DITROPA XL® is contraindicated in patients who have or are at risk of:
- urinary retention
- gastric retention, and other severe decreased gastrointestinal motility conditions
- uncontrolled narrow-angle glaucoma
- hypersensitivity to the drug substance or other components of the product. For a complete listing of the nonmedicinal ingredients, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.
WARNINGS AND PRECAUTIONS

General
As with any other nondeformable material, caution should be used when administering DITROPAN XL® to patients with pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic). There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of other drugs in nondeformable controlled-release formulations.

Patients should be informed that DITROPAN XL® should be swallowed whole with the aid of liquids. Patients should not chew, divide, or crush tablets. The medication is contained within a nonabsorbable shell designed to release the drug at a controlled rate. The tablet shell is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet.

Patients should be informed that, when administered in the presence of high environmental temperature, anticholinergics such as DITROPAN XL® can cause heat prostration (fever and heat stroke due to decreased sweating).

Because anticholinergic agents such as DITROPAN XL® may produce drowsiness (somnolence) or blurred vision, patients should be advised to exercise caution.

Alcohol or other sedative drugs may enhance the drowsiness caused by anticholinergic agents such as DITROPAN XL®.

Carcinogenesis and Mutagenesis
Non-clinical studies did not show evidence of carcinogenicity or mutagenesis. See TOXICOLOGY, Carcinogenesis and Mutagenesis.

Cardiovascular
Although there are no clinical trial or post-marketing data to confirm the potential for DITROPAN XL® to aggravate certain pre-existing cardiac conditions, this product is in the class of anticholinergic medications which are known to have cardiac effects. Prescribers should therefore use caution when prescribing DITROPAN XL® to patients with coronary heart disease, congestive heart failure, cardiac arrhythmias, tachycardia or hypertension.

Although no formal QT studies have been conducted for oxybutynin formulations, there have been very rare reports of QT interval prolongation with oxybutynin use. Newer antimuscarinic agents used in the treatment of urinary incontinence have been reported to prolong the QT/QTc interval of the electrocardiogram. Some drugs that cause QT/QTc prolongation may increase the risk of the rare, but serious ventricular arrhythmia—torsades de pointes. Patients at risk for QT/QTc prolongation, such as those with clinically relevant heart failure, long QT syndrome, recent significant hypokalemia, or receiving other drugs known to prolong QT/QTc, should be appropriately monitored when receiving oxybutynin. Patients who develop prolonged QT/QTc or symptoms of possible arrhythmia such as dizziness, palpitations, or fainting should be evaluated electrocardiographically and for electrolyte disturbances.
**Gastrointestinal**
DITROPAN XL® should be administered with caution to patients with gastrointestinal obstructive and gastrointestinal motility disorders because of the risk of gastric retention (see CONTRAINDICATIONS).

Administration of DITROPAN XL® to patients with severe ulcerative colitis may precipitate toxic megacolon.

DITROPAN XL®, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony (see CONTRAINDICATIONS).

DITROPAN XL® should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis.

DITROPAN XL® contains lactose. This medicine is not recommended for patients with rare hereditary problems of galactose intolerance (severe lactase deficiency, Lapp lactase deficiency or glucose-galactose malabsorption).

**Genitourinary**
DITROPAN XL® should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention (see CONTRAINDICATIONS).

**Hepatic**
DITROPAN XL® should be used with caution in patients with hepatic disease.

**Immune**
Angioedema of the face, lips, tongue and/or larynx has been reported with DITROPAN XL®. In some cases, angioedema occurred after the first dose. Angioedema associated with upper airway swelling has the potential to become life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, oxybutynin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.

**Neurologic**
DITROPAN XL® is associated with anticholinergic central nervous system (CNS) effects (see ADVERSE REACTIONS, Post-Market Adverse Drug Reactions). Patients should be monitored for signs of anticholinergic CNS effects (e.g., confusion, sedation, anxiety, nervousness, hallucinations, psychotic disorder, agitation and memory impairment), particularly in the first few months after beginning treatment or increasing the dose. If a patient experiences anticholinergic CNS effects, drug discontinuation or dose reduction should be considered.

DITROPAN XL®, like other anticholinergic drugs, should be administered with caution to patients with pre-existing dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.

DITROPAN XL® should be used with caution in patients with myasthenia gravis due to the risk of symptom aggravation.
DITROPAN XL® should be used with caution in patients with autonomic neuropathy.

DITROPAN XL® should be used with caution in patients with Parkinson’s disease.

**Renal**
DITROPAN XL® should be used with caution in patients with renal disease.

**Effects on Ability to Drive and Use Machines**
Because anticholinergic agents such as DITROPAN XL® may produce somnolence or blurred vision, patients should be cautioned regarding activities requiring mental alertness such as driving, operating machinery or performing hazardous work while taking this drug.

**Special Populations**

**Pregnant Women:** The safety of DITROPAN XL® administration to women who are or who may become pregnant has not been established. Therefore, DITROPAN XL® should not be given to pregnant women, unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards.

**Nursing Women:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, DITROPAN XL® should not be given to nursing women, unless, in the judgement of the physician, the probable clinical benefits outweigh the possible hazards.

**Pediatrics (< 18 years of age):** The safety and efficacy of DITROPAN XL® in children have not been established.

**Geriatrics (> 65 years of age):** The pharmacokinetics of DITROPAN XL® are similar in patients younger or older than 65 years.

**ADVERSE REACTIONS**

**Adverse Drug Reaction Overview**
The most common adverse events reported were the expected side effects of anticholinergic agents which include, but are not limited to, dry mouth, constipation and blurred vision. The incidence of dry mouth was dose related.

**Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

The safety and efficacy of DITROPAN XL® were evaluated in a total of 580 participants who received DITROPAN XL® in four clinical trials (429 patients), and four pharmacokinetic studies (151 healthy volunteers). The 429 patients were treated with 5-30 mg/day for up to 4.5 months.
Three of the four clinical trials allowed dose adjustments based on efficacy and adverse events and one was a fixed-dose escalation design.

Adverse events from the three controlled clinical studies and one open-label study in which 429 patients were treated with 5-30 mg/day of DITROPAN XL® are provided in the first column of Table 1.1. Adverse events from two additional fixed-dose, active-controlled clinical trials in which 576 patients were treated with a fixed dose of DITROPAN XL® 10 mg/day for a 12-week duration are provided in the second column of Table 1.1. The adverse events are reported regardless of causality.

For patients receiving 5-30 mg/day DITROPAN XL®, the discontinuation rate for all adverse events was 6.8%. The most frequent adverse event causing early discontinuation of study medication was nausea (1.9%). The rate and severity of anticholinergic effects reported by patients less than 65 years old and those 65 years and older were similar.

The most common adverse events reported by the 429 patients receiving 5-30 mg/day DITROPAN XL® were the expected side effects of anticholinergic agents, including dry mouth, constipation, and somnolence. The incidence of all dry mouth events at doses up to 30 mg was 60.8%; 1.2% of patients treated with DITROPAN XL® discontinued due to dry mouth. At the fixed dose of 10 mg/day, the incidence of all dry mouth events was 29.3% of which 20.8% were mild.

A complete list of pooled adverse events reported by patients participating in the four adjustable-dose and two fixed-dose studies are presented in Table 1.2. A total of 1006 subjects were treated with DITROPAN XL® (5-30 mg/day) from 3 to up to 23 weeks in these trials. Table 1.2 includes adverse events, regardless of investigator assessment of causality, reported by ≥1% of subjects in either treatment group. A dash represents an incidence of less than 1%. The adverse events for DITROSPAN immediate-release (IR) formulation, which was the comparator in three of the trials, are also presented.

Table 1.1: Incidence (%) of Adverse Events Reported by ≥5% of Patients Using DITROPAN XL® (5-30 mg/day) and % of Corresponding Adverse Events in Two Fixed-Dose (10 mg/day) Studies

<table>
<thead>
<tr>
<th>Body System</th>
<th>Adverse Event</th>
<th>DITROPAN XL® 5-30 mg/day (n = 429)</th>
<th>DITROPAN XL® 10 mg/day (n = 576)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General</td>
<td>headache</td>
<td>9.8</td>
<td>6.4</td>
</tr>
<tr>
<td></td>
<td>asthenia</td>
<td>6.8</td>
<td>3.0</td>
</tr>
<tr>
<td></td>
<td>pain</td>
<td>6.8</td>
<td>3.8</td>
</tr>
<tr>
<td>Digestive</td>
<td>dry mouth</td>
<td>60.8</td>
<td>29.3</td>
</tr>
<tr>
<td></td>
<td>constipation</td>
<td>13.1</td>
<td>6.6</td>
</tr>
<tr>
<td></td>
<td>diarrhea</td>
<td>9.1</td>
<td>7.8</td>
</tr>
<tr>
<td></td>
<td>nausea</td>
<td>8.9</td>
<td>2.4</td>
</tr>
<tr>
<td></td>
<td>dyspepsia</td>
<td>6.8</td>
<td>4.9</td>
</tr>
<tr>
<td>Nervous</td>
<td>somnolence</td>
<td>11.9</td>
<td>2.1</td>
</tr>
<tr>
<td></td>
<td>dizziness</td>
<td>6.3</td>
<td>4.2</td>
</tr>
<tr>
<td>Respiratory</td>
<td>rhinitis</td>
<td>5.6</td>
<td>1.7</td>
</tr>
<tr>
<td>Special senses</td>
<td>blurred vision</td>
<td>7.7</td>
<td>1.6</td>
</tr>
<tr>
<td></td>
<td>dry eyes</td>
<td>6.1</td>
<td>3.1</td>
</tr>
<tr>
<td>Urogenital</td>
<td>urinary tract infection</td>
<td>5.1</td>
<td>5.2</td>
</tr>
</tbody>
</table>
Table 1.2: Adverse Events Reported by \( \geq 1\% \) of Subjects in Either Treatment Group in Clinical Trials of DITROPAN XL®

<table>
<thead>
<tr>
<th>System/Organ Class Preferred Term</th>
<th>% DITROPAN XL® subjects reporting event (n = 1006)</th>
<th>% DITROPAN IR® subjects reporting event (n = 199)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infections and Infestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>5.2</td>
<td>6.5</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>2.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>2.2</td>
<td>2.5</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>1.7</td>
<td>-</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>1.2</td>
<td>2.0</td>
</tr>
<tr>
<td>Cystitis</td>
<td>1.2</td>
<td>1.0</td>
</tr>
<tr>
<td><strong>Psychiatric Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>2.8</td>
<td>5.5</td>
</tr>
<tr>
<td>Depression</td>
<td>1.7</td>
<td>--</td>
</tr>
<tr>
<td>Nervousness</td>
<td>1.5</td>
<td>6.5</td>
</tr>
<tr>
<td>Confusional state</td>
<td>1.0</td>
<td>2.5</td>
</tr>
<tr>
<td><strong>Nervous System Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>7.8</td>
<td>7.5</td>
</tr>
<tr>
<td>Somnolence</td>
<td>5.7</td>
<td>14.0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>4.9</td>
<td>16.6</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>1.1</td>
<td>1.5</td>
</tr>
<tr>
<td><strong>Eye Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keratoconjunctivitis sicca</td>
<td>4.2</td>
<td>2.5</td>
</tr>
<tr>
<td>Vision blurred</td>
<td>4.2</td>
<td>9.6</td>
</tr>
<tr>
<td><strong>Cardiac Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palpitations</td>
<td>1.5</td>
<td>4.5</td>
</tr>
<tr>
<td><strong>Vascular Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>1.3</td>
<td>--</td>
</tr>
<tr>
<td><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal dryness</td>
<td>2.8</td>
<td>4.5</td>
</tr>
<tr>
<td>Cough</td>
<td>2.4</td>
<td>3.0</td>
</tr>
<tr>
<td>Pharyngolaryngeal pain</td>
<td>1.9</td>
<td>1.5</td>
</tr>
<tr>
<td>Dry throat</td>
<td>1.6</td>
<td>2.5</td>
</tr>
</tbody>
</table>
Table 1.2 (cont’d): Adverse Events Reported by ≥ 1% of Subjects in Either Treatment Group in Clinical Trials of DITROPAN XL®

<table>
<thead>
<tr>
<th>System/Organ Class</th>
<th>% DITROPAN XL® subjects reporting event (n = 1006)</th>
<th>% DITROPAN IR® subjects reporting event (n = 199)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td>41.6</td>
<td>71.4</td>
</tr>
<tr>
<td>Constipation</td>
<td>9.1</td>
<td>15.1</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>6.8</td>
<td>3.5</td>
</tr>
<tr>
<td>Nausea</td>
<td>5.2</td>
<td>11.6</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>4.7</td>
<td>6.0</td>
</tr>
<tr>
<td>Gastroesophageal reflux disease</td>
<td>1.6</td>
<td>--</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>1.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Loose stools</td>
<td>1.4</td>
<td>3.0</td>
</tr>
<tr>
<td>Flatulence</td>
<td>1.2</td>
<td>2.5</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1.2</td>
<td>1.5</td>
</tr>
<tr>
<td>Skin and Subcutaneous Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry skin</td>
<td>2.6</td>
<td>3.0</td>
</tr>
<tr>
<td>Pruritus</td>
<td>1.3</td>
<td>1.5</td>
</tr>
<tr>
<td>Musculoskeletal and Connective Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>2.4</td>
<td>2.0</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>1.5</td>
<td>2.0</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>1.3</td>
<td>1.0</td>
</tr>
<tr>
<td>Renal and Urinary Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary retention</td>
<td>4.7</td>
<td>6.0</td>
</tr>
<tr>
<td>Urinary hesitation</td>
<td>2.3</td>
<td>8.5</td>
</tr>
<tr>
<td>Dysuria</td>
<td>1.7</td>
<td>2.5</td>
</tr>
<tr>
<td>General Disorders and Administration Site Conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>3.1</td>
<td>3.0</td>
</tr>
<tr>
<td>Edema peripheral</td>
<td>2.5</td>
<td>4.0</td>
</tr>
<tr>
<td>Asthenia</td>
<td>1.7</td>
<td>2.5</td>
</tr>
<tr>
<td>Chest pain</td>
<td>1.3</td>
<td>--</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure increased</td>
<td>1.0</td>
<td>1.5</td>
</tr>
</tbody>
</table>

Note: Includes adverse events, regardless of investigator assessment of causality, reported by ≥1% of the subjects in either treatment group.
Less Common Clinical Trial Adverse Drug Reactions (≤1%)
Additional adverse drug reactions reported from clinical trials with DITROPAN XL® with incidences < 1% and consequently not reported in Tables 1.1 or 1.2 above are listed below.

Vascular Disorders: hot flush;
Respiratory, Thoracic and Mediastinal Disorders: dysphonia, throat irritation;
Gastrointestinal Disorders: abdominal discomfort, frequent bowel movements;
Renal and Urinary Disorders: residual urine;
General Disorders and Administration Site Conditions: chest discomfort, mucosal dryness (multiple sites)

Post-Market Adverse Drug Reactions
Additional adverse drug reactions reported from worldwide post-marketing experience with DITROPAN XL® include:

Eye Disorders: Glaucoma;
Immune System Disorders: anaphylactic reaction, hypersensitivity;
Psychiatric Disorders: hallucinations; psychotic disorder, agitation, memory impairment, and abnormal behaviour;
Nervous System Disorders: convulsions;
Cardiac Disorders: arrhythmia, tachycardia;
Vascular Disorders: flushing;
Skin and Subcutaneous Tissue Disorders: rash, angioedema, urticaria;
Urogenital Disorders: impotence;
Injury, Poisoning and Procedural Complications: fall;
Metabolism and Nutrition Disorders: anorexia

Other Oxybutynin Formulations
Other adverse events have been reported with other oxybutynin formulations: cycloplegia, mydriasis, suppression of lactation and QT interval prolongation.

DRUG INTERACTIONS

Overview
The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.

Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may also antagonize the effects of prokinetic agents, such as metoclopramide and domperidone.

Drug-Drug Interactions
Mean oxybutynin plasma concentrations were approximately two-fold higher when DITROPAN XL® was administered with ketoconazole, a potent CYP3A4 inhibitor.
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antifungal agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., $C_{\text{max}}$ and AUC). The clinical relevance of such potential interactions is not known. Caution should be used when such drugs are co-administered.

Concurrent ingestion of an antacid (20 mL of an antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) with DITROPAN XL® did not significantly affect the exposure of oxybutynin or desethyl oxybutynin.

Concurrent ingestion of a proton pump inhibitor (20 mg omeprazole) with DITROPAN XL® did not significantly affect the exposure of oxybutynin or desethyl oxybutynin.

**Drug-Food Interactions**
The rate and extent of absorption and metabolism of oxybutynin are similar under fed and fasted conditions.

**Drug-Herb Interactions**
Interactions with herbal products have not been established.

**Drug-Lifestyle Interactions**
Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as oxybutynin.

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**
DITROPAN XL® is administered orally once daily.

DITROPAN XL® must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed.

DITROPAN XL® may be administered with or without food.

DITROPAN XL® should be taken at a consistent time each day.

**Recommended Dose and Dosage Adjustment**

**Initiating Therapy**
In adults ($\geq$ 18 years of age), the recommended starting dose of DITROPAN XL® is 5 or 10 mg once daily at a consistent time each day. The dosage may be adjusted in 5 mg increments to achieve a balance of efficacy and tolerability (up to a maximum of 30 mg/day). In general, dosage adjustment may proceed at approximately weekly intervals.

**Converting from Immediate-Release Formulations to DITROPAN XL®**
Patients already taking immediate-release oxybutynin tablets may be switched to the nearest equivalent total daily dose of DITROPAN XL®. Patients who are not fully continent on immediate-release oxybutynin may tolerate higher doses of DITROPAN XL®, administered in 5 mg increments, and may achieve a greater improvement in their incontinence symptoms. Subsequent adjustment to higher or lower doses should be initiated as clinically warranted.
**Missed Dose**
The missed dose should be taken as soon as possible. If it is almost time for the next dose, the missed dose should not be taken. Instead, the next scheduled dose should be taken. Doses should not be doubled.

**OVERDOSAGE**
The continuous release of oxybutynin from DITROPAN XL® (oxybutynin chloride) should be considered in the treatment of overdosage. Patients should be monitored for at least 24 hours. Treatment should be symptomatic and supportive. A cathartic may be administered.

Overdosage with oxybutynin has been associated with anticholinergic effects including CNS excitation, flushing, fever, dehydration, cardiac arrhythmia, vomiting, and urinary retention. These anticholinergic effects may range from mild to severe.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Ingestion of 100 mg oxybutynin chloride in association with alcohol has been reported in a 13-year-old boy who experienced memory loss, and a 34-year-old woman who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine. Both patients fully recovered with symptomatic treatment.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action**

DITROPAN XL® contains the active ingredient oxybutynin chloride, a tertiary amine anticholinergic agent which exerts antimuscarinic as well as direct antispasmodic action on smooth muscle. In addition to its smooth muscle relaxing effects, oxybutynin chloride exerts an analgesic and a local anesthetic effect.

Oxybutynin chloride relaxes bladder smooth muscle. In patients with uninhibited neurogenic and reflex neurogenic bladder, cystometric studies have demonstrated that oxybutynin chloride increases bladder (vesical) capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle, and delays the initial desire to void. DITROPAN XL® thus decreases urgency and frequency of both incontinent episodes and voluntary urination.

**Pharmacodynamics**

Several studies have assessed oxybutynin’s urodynamic effect (increase in bladder capacity) as measured by cystometry. The onset of action was rapid (within 1 h) following 5 mg oral oxybutynin chloride. The effect was seen up to 10 hours post-drug administration. Intravesical administration of oxybutynin chloride has also shown increase in bladder capacity within 1-1.5 h after drug instillation.
Pharmacokinetics

Absorption: Oxybutynin chloride is readily absorbed from the gastrointestinal tract. Following the first dose of DITROPAN XL®, oxybutynin plasma concentrations rise for 4 to 6 hours; thereafter, steady concentrations are maintained for up to 24 hours.

The relative bioavailabilities of R- and S-oxybutynin from DITROPAN XL® are 156% and 187%, respectively, compared with immediate-release oxybutynin chloride tablets. The mean pharmacokinetic parameters for R- and S-oxybutynin are summarized in Table 1.3. The plasma concentration-time profiles for R- and S-oxybutynin are similar in shape; Figure 1.1 shows the profile for R-oxybutynin.

<table>
<thead>
<tr>
<th>Parameters (units)</th>
<th>R-Oxybutynin</th>
<th>S-Oxybutynin</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</td>
<td>1.0 (0.6)</td>
<td>1.8 (1.0)</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (h)</td>
<td>12.7 (5.4)</td>
<td>11.8 (5.3)</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt; (h)</td>
<td>13.2 (6.2)</td>
<td>12.4 (6.1)</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;(0-48)&lt;/sub&gt; (ng·h/mL)</td>
<td>18.4 (10.3)</td>
<td>34.2 (16.9)</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;inf&lt;/sub&gt; (ng·h/mL)</td>
<td>21.3 (12.2)</td>
<td>39.5 (21.2)</td>
</tr>
</tbody>
</table>

Figure 1.1. Mean R-oxybutynin plasma concentrations following a single dose of DITROPAN XL® 10 mg and immediate-release (IR) oxybutynin 5 mg administered every 8 hours (n=23 for each treatment).

Steady-state oxybutynin plasma concentrations are achieved by Day 3 of repeated DITROPAN XL® dosing, with no drug accumulation or change in oxybutynin and desethyloxybutynin pharmacokinetic parameters. The rate and extent of absorption and metabolism of oxybutynin are similar under fed and fasted conditions.

Distribution: Oxybutynin is widely distributed in body tissues following systemic absorption. The volume of distribution is 193 L after intravenous administration of 5 mg oxybutynin chloride. Both enantiomers of oxybutynin are highly bound (>99%) to plasma proteins. Both enantiomers of desethyloxybutynin are also highly bound (>97%) to plasma proteins. The major binding protein is alpha-1 acid glycoprotein.
**Metabolism:** Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4 found mostly in the liver and gut wall. Its metabolic products include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and desethyloxybutynin, which is pharmacologically active. Following DITROPAN XL® administration, plasma concentrations of R- and S-desethyloxybutynin are 73% and 92%, respectively, of concentrations observed with immediate-release oxybutynin chloride tablets.

**Excretion:** Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine.

**Dose Proportionality:** Pharmacokinetic parameters of oxybutynin and desethyloxybutynin (C_{max} and AUC) following administration of DITROPAN XL® are dose proportional.

**Special Populations and Conditions**

**Pediatrics (<18 years of age):** The pharmacokinetics of DITROPAN XL® were not evaluated in individuals younger than 18 years of age. The pharmacokinetics of immediate-release oxybutynin chloride in children (5-13 years) are similar to those in adults.

**Geriatrics (>65 years of age):** The pharmacokinetics of DITROPAN XL® are similar in patients younger or older than 65 years.

**Gender:** There are no significant differences in the pharmacokinetics of oxybutynin in healthy male and female volunteers following administration of DITROPAN XL®.

**Race:** Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on race in healthy volunteers following administration of DITROPAN XL®.

**Hepatic Insufficiency:** There is no experience with the use of DITROPAN XL® in patients with hepatic insufficiency. Use DITROPAN XL® with caution in patients with hepatic insufficiency.

**Renal Insufficiency:** There is no experience with the use of DITROPAN XL® in patients with renal insufficiency. Use DITROPAN XL® with caution in patients with renal insufficiency.

**STORAGE AND STABILITY**

Store between 15 and 30°C. Protect from moisture and humidity. Keep out of reach and sight of children.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**

**Dosage Forms**

DITROPAN XL® round, extended-release tablets are available in two dosage strengths, 5 mg (pale yellow) and 10 mg (pink), imprinted with “5 XL” or “10 XL”, respectively.

**Composition**

Inactive Ingredients: Each tablet contains butylated hydroxytoluene, cellulose acetate, hydroxypropyl methylcellulose, lactose, magnesium stearate, polyethylene glycol, polyethylene
oxide, polysorbate 80, propylene glycol, sodium chloride, synthetic iron oxides and titanium dioxide.

**Packaging**
Supplied in bottles of 100 tablets.

**System Components and Performance**
DITROPAN XL® uses osmotic pressure to deliver oxybutynin chloride at a controlled rate over approximately 24 hours. The system, which resembles a conventional tablet in appearance, comprises an osmotically active bilayer core surrounded by a semi-permeable membrane. The bilayer core is composed of a drug layer containing the drug and excipients, and a push layer containing osmotically active components. There is a precision-laser drilled orifice in the semi-permeable membrane on the drug-layer side of the tablet. In an aqueous environment, such as the gastrointestinal tract, water permeates through the membrane into the tablet core, causing the drug to go into suspension and the push layer to expand. This expansion pushes the suspended drug out through the orifice. The semi-permeable membrane controls the rate at which water permeates into the tablet core, which in turn controls the rate of drug delivery. The controlled rate of drug delivery into the gastrointestinal lumen is thus independent of pH or gastrointestinal motility. The function of DITROPAN XL® depends on the existence of an osmotic gradient between the contents of the bilayer core and the fluid in the gastrointestinal tract. Since the osmotic gradient remains constant, drug delivery remains essentially constant. The biologically inert components of the tablet remain intact during gastrointestinal transit and are eliminated in the feces as an insoluble shell.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: oxybutynin chloride

Chemical name: benzeneacetic acid, α-cyclohexyl-α-hydroxy-, 4-(diethylamino)-2-butynyl ester hydrochloride, (±)- 4-(Diethylamino)-2-butynyl (±)-α-phenyleclohexaneglycolate hydrochloride.

Molecular formula and molecular mass: \( \text{C}_{22}\text{H}_{31}\text{NO}_3 \cdot \text{HCl} \); 393.9

Structural formula:

![Structural formula of oxybutynin chloride](image)

Physicochemical properties: oxybutynin chloride is a white crystalline solid, readily soluble in water and acids, but relatively insoluble in alkalies. The melting point is 124E-129EC.

CLINICAL TRIALS

The efficacy and safety of DITROPAN XL® were demonstrated in three controlled studies and one open-label study in 669 adult patients (age range 18-98 years, mean age 59 years) with urge or mixed (urge and stress) urinary incontinence. Study 1 was a forced dose-escalation design, whereas all other studies were dose-adjustment studies, in which each patient’s final dose was adjusted to a balance between improvement in incontinence symptoms and tolerability (Table 2.1).

<table>
<thead>
<tr>
<th>Study No.</th>
<th>Treatment (No. of patients)</th>
<th>Dose mg/day</th>
<th>% Reduction in Urge Episodes*</th>
<th>% Patients Continent at Endpoint (p-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>DITROPAN XL® (34)</td>
<td>5, 10, 15</td>
<td>90</td>
<td>50 (0.003 vs. placebo)</td>
</tr>
<tr>
<td></td>
<td>Placebo (16)</td>
<td>(5, 10, 15)</td>
<td>49</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>IR oxybutynin (32)</td>
<td>5, 10, 15</td>
<td>77</td>
<td>28 (0.06 vs. active)</td>
</tr>
<tr>
<td>2</td>
<td>DITROPAN XL® (53)</td>
<td>5 - 30</td>
<td>84</td>
<td>41 (0.9)</td>
</tr>
<tr>
<td></td>
<td>IR oxybutynin (52)</td>
<td>5 - 20</td>
<td>88</td>
<td>40</td>
</tr>
<tr>
<td>3</td>
<td>DITROPAN XL® (111)</td>
<td>5 - 20</td>
<td>83</td>
<td>42 (0.17)</td>
</tr>
<tr>
<td></td>
<td>IR oxybutynin (115)</td>
<td>5 - 20</td>
<td>76</td>
<td>34</td>
</tr>
<tr>
<td>4</td>
<td>DITROPAN XL® (256)</td>
<td>5 - 30</td>
<td>85</td>
<td>44</td>
</tr>
</tbody>
</table>

*All reductions are significantly different at endpoint from baseline (p<0.01).
Study 1
This multi-centre, randomized, double-blind, forced dose-escalation study in 82 women compared the efficacy and safety of DITROPAN XL\textsuperscript{®} to oral placebo. DITROPAN XL\textsuperscript{®} was significantly more effective than placebo (p=0.001) in reducing urge incontinence episodes (from 15.9 to 1.5 episodes per week). Patients treated with DITROPAN XL\textsuperscript{®} experienced a 90% mean decrease in weekly urge incontinence episodes (from 15.9 to 1.5 episodes per week). Significantly more patients in the DITROPAN XL\textsuperscript{®} group than in the placebo group were completely continent (p=0.003, 50% vs. 13%, respectively). Void frequency, in terms of weekly micturitions, was reduced by a mean of 23% (from 85.2 to 65.9 micturitions per week). Mean pad usage was reduced from 12.2 per week at baseline to 2.2 at endpoint in patients treated with DITROPAN XL\textsuperscript{®} (p<0.001 vs. placebo).

Study 2
This multi-centre, randomized, double-blind, active-control, parallel-group study in 105 men and women compared the efficacy and safety of DITROPAN XL\textsuperscript{®} to immediate-release oxybutynin. Patients treated with DITROPAN XL\textsuperscript{®} experienced an 84% mean decrease in weekly urge incontinence episodes. The difference in mean decrease in weekly urge incontinence episodes between DITROPAN XL\textsuperscript{®} and oxybutynin chloride was not statistically significant (84% [from 27.3 to 4.8 per week] and 88% [from 21.3 to 3.1 per week], respectively). The percent of patients completely continent at endpoint was comparable in the DITROPAN XL\textsuperscript{®} group and the immediate-release oxybutynin group (41% vs. 40%, respectively). Fewer patients treated with DITROPAN XL\textsuperscript{®} experienced moderate and severe dry mouth compared to patients treated with immediate-release oxybutynin (25% vs. 46%, respectively).

Study 3
This multi-centre, double-blind, randomized, parallel-group study in 226 men and women evaluated the safety and efficacy of DITROPAN XL\textsuperscript{®} and immediate-release oxybutynin. Patients treated with DITROPAN XL\textsuperscript{®} experienced an 83% mean decrease in weekly urge incontinence episodes (from 18.6 to 2.9 per week), and patients treated with oxybutynin chloride experienced a 76% mean decrease (from 19.8 to 4.4 per week). The efficacy between the treatment groups was comparable. The percent of patients completely continent at endpoint was comparable in the DITROPAN XL\textsuperscript{®} group and the immediate-release oxybutynin group (42% vs. 34%, respectively). Fewer patients treated with DITROPAN XL\textsuperscript{®} experienced moderate and severe dry mouth compared to patients treated with immediate-release oxybutynin (17% vs. 26%, respectively).

DITROPAN XL\textsuperscript{®} demonstrated comparable efficacy to immediate-release oxybutynin chloride in all three controlled clinical trials.

A Kaplan-Meier survival analysis of two comparative trials (Studies 2, 3) demonstrated that comparable proportions of patients treated with DITROPAN XL\textsuperscript{®} and immediate-release oxybutynin achieved complete continence at each dose level (p=0.75).

The incidences of moderate or severe dry mouth and of any severity of dry mouth in patients treated with DITROPAN XL\textsuperscript{®} were similar to those in patients treated with 5 mg less of immediate-release oxybutynin chloride.
Study 4
A noncontrolled study evaluated the safety (n=256) and efficacy (n=219) of DITROPAN XL® prolonged release (PR), up to 30 mg/day, for up to 23 weeks of treatment, and evaluated the dose recommendations for dose conversion from other U-UI medications to DITROPAN XL®. Patients were either drug-naïve (n=185), or previously treated with other U-UI drugs (n=71). There was no washout period for patients previously treated with other U-UI drugs; other U-UI drugs were stopped during the dose-conversion portion of the study, with next-day conversion to DITROPAN XL®. Patients previously treated with DITROPAN® immediate release (IR) for urge urinary incontinence (n=43) were switched at start of PR dosing to the same total daily dose of DITROPAN XL® as their DITROPAN® IR dose, and then were dose adjusted to a balance between improvement in incontinence symptoms and tolerability. Taking into account both naïve patients and patients previously treated with other U-UI drugs, patients had an 85% decrease in mean weekly urge incontinence episodes; the mean number of weekly urge incontinence episodes was 18.8 at baseline, 3.9 at week 1, and 2.8 at endpoint. The mean weekly void frequency for all patients (naïve and previously treated with other U-UI drugs) was 81 micturitions at baseline and 67 micturitions at endpoint. At the end of the study, over 40% of patients achieved complete continence (43.8% overall, 43.4% of drug-naïve patients, 45.0% previously treated with any U-UI drug, and 45.9% previously treated with DITROPAN® IR only). Baseline values for mean weekly void frequency were not established in patients switching from the IR formulation.

DETAILED PHARMACOLOGY

Animal Pharmacology

In Vitro
In vitro studies have shown that the anticholinergic effects of oxybutynin chloride are weaker than those of atropine, but it possesses greater antispasmodic activity. No blocking effects occur at skeletal neuromuscular junctions or in autonomic ganglia (no antinicotinic effects).

In a series of in vitro tests, oxybutynin chloride was found to be more effective than propantheline, methantheline and atropine in inhibiting barium chloride-induced contractions in rabbit bladder detrusor muscle. It was, however, less active than the other drugs in inhibiting contractions caused by histamine and carbamylcholine.

In vitro studies using preparations for rabbit vas deferens, guinea pig atria, bladder, and ileal longitudinal muscle suggest that the antimuscarinic activity resides predominantly in the R-isomer. In vitro studies with human detrusor preparations showed that the metabolite desethyloxybutynin has pharmacological activity similar to that of oxybutynin.

In Vivo
Oxybutynin chloride was more effective than atropine in relieving morphine-induced spasm in the anesthetized dog. Atropine had a partial effect, presumably due to the musculotropic component of its action, while methscopolamine, a neurotropic compound, was ineffective. Against neostigmine-induced spasm, oxybutynin chloride showed about 15% of the potency of atropine. These results suggest that the major antispasmodic activity of oxybutynin chloride is musculotropic rather than neurotropic.
In animal studies, the central nervous system and cardiovascular actions of oxybutynin were shown to be similar to but weaker than those of atropine.

Oxybutynin chloride was less potent than atropine in producing mydriasis in the mouse and in inhibiting the sialogogic response in dogs.

In tests for analgesic activity, oxybutynin chloride was shown to be 35% as potent as codeine in the mouse tail-clip test and approximately equal to acetylsalicylic acid in the acetic acid stretch test. It was approximately twice as potent as lidocaine in producing local anesthesia in the rabbit cornea.

Oxybutynin chloride was less potent than atropine but similar in potency to methscopolamine in producing characteristic anticholinergic CNS effects in dogs. The cardiovascular actions of oxybutynin chloride in the anesthetized dog were also relatively weak.

Using oxybutynin chloride doses at least seven times greater than the maximum recommended therapeutic dosage, the following results were obtained in various drug interaction tests: Dicumarol effects were potentiated; hexobarbital sleep time was not significantly affected; oxazolamine paralysis time was not significantly affected; there were no effects on aniline or hexobarbital hydroxylation; O-demethylation of codeine was possibly inhibited; the nitro-reduction of codeine was possibly inhibited; the nitro-reduction of p-aminobenzoic acid was stimulated; and oxphenbutazone metabolism was not affected.

_In vivo_ studies with volume-induced urinary bladder contractions as measured by cystometrogram in guinea pigs support _in vitro_ evidence that the antimuscarinic activity resides with the R-isomer.

### TOXICOLOGY

**Acute Toxicity**
A summary of the acute toxicity studies performed with oxybutynin chloride is presented in Table 2.2.

**Table 2.2: Single-dose toxicity studies with oxybutynin chloride**

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>LD&lt;sub&gt;50&lt;/sub&gt; (95% C.L.)*</th>
<th>Slope (95% C.L.)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>P.O.</td>
<td>1550 mg/kg (1372-1751)</td>
<td>1.69 (1.48-1.93)</td>
</tr>
<tr>
<td>Mouse</td>
<td>I.P.</td>
<td>260 mg/kg (186-346)</td>
<td>2.2 (1.6-3.1)</td>
</tr>
<tr>
<td>Mouse</td>
<td>I.V.</td>
<td>40 mg/kg (36-45)</td>
<td>1.25 (1.1–1.4)</td>
</tr>
<tr>
<td>Rat</td>
<td>P.O.</td>
<td>1600 mg/kg (1176-2176)</td>
<td>1.94 (1.39-2.72)</td>
</tr>
<tr>
<td>Rat</td>
<td>I.P.</td>
<td>430 mg/kg (371-499)</td>
<td>1.32 (1.21-1.4)</td>
</tr>
</tbody>
</table>
Newborn Rat  P.O.  560 mg/kg (528-594)  1.07 (0.82-1.39)
                      Approximate Minimum Lethal Dose
                      Dog  I.V.  > 25 but < 50 mg/kg
                      Dog  P.O.  > 750 but < 1000 mg/kg
* 95% confidence limits

Signs and symptoms of toxicity in mice and rats were exophthalmos, CNS stimulation, ataxia and convulsions. In rats receiving the drug orally, intraocular tension was increased in some animals at each dose level. Females were more susceptible to toxicity and mortality than males. In newborn rats, laboured respiration and decreased activity were the only toxic symptoms noted, with most deaths occurring on day 2. Mydriasis, hyperventilation, ataxia, emesis, muscular weakness of hind limbs and convulsions were commonly seen in dogs.

**Subacute and Chronic Toxicity**
In a three-month study, 0, 50, 100, and 150 mg/kg/day of oxybutynin chloride were administered orally to groups of 20 rats. At the highest dose, mortality was approximately 50%, while at lower doses it did not differ significantly from the control rate. Other effects observed at high dosage were ataxia, depression, hypersensitivity to stimulation and pilomotor erection.

In a six-month rat study, 20-200 mg/kg/day p.o. was administered 6 days per week. At the lowest dose no significant toxic effects were observed, while rats receiving 63-200 mg/kg/day showed signs of continuous acute pharmacologic effects, decreased food consumption with suppression of weight gain, and somewhat dose-related pathological changes consisting primarily of irregular and enlarged hepatic cells and of degenerative changes in kidney tubules.

In a two-year oral study in rats, 0, 20, 80 and 160 mg/kg/day were given to 50 animals of each sex per group. No high-dose and only a few mid-dose animals survived beyond 90 weeks. A dose-related reduction in weight gain was observed at all dose levels. Slight mydriasis was noted in a few rats at 20 mg/kg/day and mydriasis, tenseness, hyperactivity and excessive salivation in the higher dose groups. Serum alkaline phosphatase values for most high-dose rats were slightly higher than those of controls at most intervals of analysis. Microscopic examination of the urine showed an increase in the number of red and white blood cells in mid-dose males and in the number of red cells in high-dose males at termination. No other drug-related changes were observed in hematology, ophthalmologic examinations, organ weights, gross pathology or histopathology. Tumour incidence was similar in the control and experimental groups.

A six-month study in dogs showed no toxic effects following administration of 3 and 6 mg/kg/day of oxybutynin chloride 6 days per week, while higher doses produced anorexia, tremors and nervousness during the first weeks. These signs of toxicity diminished during the remainder of the study and no other abnormalities were observed.

Groups of 4 male and 4 female beagle dogs received 0, 4, 8 and 16 mg/kg/day p.o. for one year. Dogs in the 16 mg/kg/day group were initiated at 4 mg/kg b.i.d. and the dose was gradually increased over 8 weeks to 8 mg/kg b.i.d. There were no mortalities. Dry oral mucous membranes and mydriasis were noted in all treated dogs. Some animals at 8 and 16 mg/kg/day
had a dry nose, and at the highest dose level occasional increased activity, purulent ocular or nasal discharge, emaciation and/or dehydration were also observed. A dose-related decrease in body weight was seen at all dose levels, although food consumption did not differ significantly from control values.

Slightly microcytic normochromic erythrocytes were noted in a few treated dogs after one month only. Slight decreases in erythrocyte count, hemoglobin concentration and hematocrit values were noted in the 16 mg/kg/day group at all intervals of analysis. No other drug-related changes were seen in hematologic, biochemical or urinalysis values, in ophthalmoscopic examinations, or in electrocardiograms, and no gross or microscopic pathologic lesions or significant variations in organ weight were observed in any treated dogs.

A 30-day oral toxicity study examined the local gastrointestinal (GI) and systemic effects in beagle dogs that received OROS® (oxybutynin chloride) daily for 30 days. Two doses of OROS® oxybutynin were evaluated: 40 and 45 mg/d, ~3.6 or 4.1 mg/kg/d. DITROPAN® tablets (40 mg/d, ~3.6 mg/kg/d) were used as an active comparator. There was no treatment-related GI irritation or other significant signs of systemic toxicity at doses approximately 10 times greater than the maximum proposed human dose of 30 mg/d (~0.43 mg/kg/d).

**Reproductive Studies**

Twenty female rats per group were administered 0, 20, and 160 mg/kg/day orally from day 6 to 16 of gestation. Dams were sacrificed on day 20 and fetuses examined. One dam in the 20 mg/kg/day group died during the gestation period. Slight mydriasis was noted at the low dose and slight to marked mydriasis and occasional tenseness at the high dose. No drug-related effects on any fetal parameters evaluated were observed at either dose level.

The teratogenic potential of oxybutynin chloride has also been studied in mice, hamsters and rabbits at doses of up to 180 mg/kg/day. No abnormalities were observed.

Reproduction studies with oxybutynin chloride in the mouse, rat, hamster, and rabbit showed no definite evidence of impaired fertility.

**Carcinogenesis and Mutagenesis**

A 24-month study in rats at dosages of oxybutynin chloride of 20, 80, and 160 mg/kg/day showed no evidence of carcinogenicity. These doses are approximately 6, 25, and 50 times the maximum human exposure, based on surface area.

Oxybutynin chloride showed no increase of mutagenic activity when tested in *Schizosaccharomyces pompholiciformis*, *Saccharomyces cerevisiae*, and *Salmonella typhimurium* test systems.
REFERENCES


PART III: CONSUMER INFORMATION

"DITROPAN XL®
oxybutynin chloride
Extended-release Tablets

This leaflet is Part III of a three-part “Product Monograph” published when DITROPAN XL® was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about DITROPAN XL®. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for: DITROPAN XL® is used to relieve the symptoms of overactive bladder which include the frequent and urgent need to urinate with or without urine leakage.

DITROPAN XL® use in patients under 18 years of age has not been established.

What it does: DITROPAN XL® relaxes the smooth muscle of the bladder which results in a decreased urgency and frequency of urination and episodes of urine leakage.

When it should not be used: Do not take DITROPAN XL® if you:

- have difficulty urinating, or stomach problems affecting passage and digestion of food
- have uncontrolled narrow-angle glaucoma (high pressure and pain in the eyes)
- are allergic to oxybutynin chloride or any of the other ingredients in DITROPAN XL® (see What the nonmedicinal ingredients are).

What the medicinal ingredient is:
oxbytynin chloride

What the nonmedicinal ingredients are:
butylated hydroxytoluene, cellulose acetate, hydroxypropyl methylcellulose, lactose, magnesium stearate, polyethylene glycol, polyethylene oxide, polysorbate 80, propylene glycol, sodium chloride, synthetic iron oxides and titanium dioxide.

What dosage forms it comes in:
extended-release tablets: 5 and 10 mg

WARNINGS AND PRECAUTIONS

BEFORE you use DITROPAN XL®, talk to your doctor or pharmacist if you:

- have stomach or intestine (gut) problems affecting passage and digestion of food
- have glaucoma (high pressure and pain in the eyes)
- have gastroesophageal reflux (heartburn) or are taking drugs (such as bisphosphonates which are used to prevent bone thinning and fractures caused by osteoporosis) that can worsen esophagitis (inflammation of the tube that connects the mouth and the stomach)
- have ulcerative colitis (inflammatory bowel disease)
- have myasthenia gravis (a muscle weakening disease)
- have heart problems
- have kidney and liver problems
- take certain drugs for treatment of dementia (such as Alzheimer’s disease)
- have autonomic neuropathy (a nerve disorder that affects heart rate, blood pressure, sweating and digestion)
- have Parkinson’s disease
- have difficulty urinating
- are pregnant or trying to become pregnant
- are breast-feeding
- have one of the following rare hereditary diseases:
  - Galactose intolerance
  - Lapp lactase deficiency
  - Glucose-galactose malabsorption

Because lactose is a non-medicinal ingredient in DITROPAN XL®.

DITROPAN XL® is contained within a nonabsorbable shell designed to release the drug at a controlled rate. It is normal that the shell that looks like a tablet may pass through the stomach and intestine and appears in the stool.

In hot weather, DITROPAN XL® can cause heat prostration (fever and heat stroke due to decreased sweating).

Driving and using machines: DITROPAN XL® may produce drowsiness or blurred vision. Do not drive or operate machinery until you know how the medication affects you.

Alcohol may add to the drowsiness caused by DITROPAN XL®.

DITROPAN XL® may cause central nervous system (CNS) effects (symptoms referring to changes in thinking or emotions) such as anxiety, nervousness, difficulty remembering, seeing or hearing things that are not actually there, and trouble thinking clearly or making decisions. If you experience any CNS effects, please contact your doctor immediately.

DITROPAN XL® may cause severe allergic reactions such as swelling of the face, lips, tongue, and upper airway that may become life-threatening.

INTERACTIONS WITH THIS MEDICATION

Always tell your doctor about all medicines you are taking. Your doctor will decide if it is safe for you to use DITROPAN XL® with other medicines. If you take any of the following medicines with DITROPAN XL®, it may affect how well they work or increase the likelihood of side effects:

- drugs that could result in serious adverse effects if small changes in dosage occur (such as digoxin for heart problems)
- other anticholinergic drugs, used to treat a number of different medical conditions (a few examples are atropine for glaucoma or hyoscine for nausea), or drugs with similar undesired effects (such as dry mouth, constipation, drowsiness and blurred vision)
- certain antibiotics (such as erythromycin and clarithromycin)
• certain drugs for the treatment of fungal infections (such as oral ketoconazole, itraconazole, and miconazole)
• drugs used to help empty the stomach and move foods through the gut (such as domperidone and metoclopramide)

PROPER USE OF THIS MEDICATION

DITROPAN XL® tablets should be swallowed whole with water or liquids. Do not chew, divide, or crush the tablets.

DITROPAN XL® may be taken with or without food.

Take DITROPAN XL® by mouth once daily.

Usual adult dose:
The recommended starting dose of DITROPAN XL® is 5 or 10 mg once daily at a consistent time each day. The maximum daily dose is 30 mg. Your dose may be adjusted as recommended by your doctor.

Overdose:
If you take too much DITROPAN XL®, you may experience:
nerve system excitation (such as restlessness, tremor, irritability, confusion, and hallucinations), flushing (usually of the face or neck), fever, dehydration, heart beat irregularities, vomiting, and difficulty emptying your bladder completely.

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed dose:
If you miss a dose, take it as soon as you remember. If it is almost time for the next dose, do not take the missed dose. Instead, take the next scheduled dose. Do not try to make up for the missed dose by taking a double dose next time.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, DITROPAN XL® can cause side effects, although not everyone gets them. The following side effects may occur with this medicine:

Very common side effects (may affect more than 1 in 10 people):
• Dry mouth

Common side effects (affects less than 1 in 10 people):
• Pain passing urine
• Delay when starting to pass urine
• Bladder cannot be fully emptied (residual urine)
• Urinary tract infection
• Stuffy nose (rhinitis)
• Back pain, joint pain
• Swelling feet and hands (retaining water)
• Constipation, diarrhea, indigestion, nausea, vomiting, stomach pain, flatulence, heartburn
• Problems sleeping

• Feeling sleepy, feeling tired
• Cough, sore or dry throat, dry nose
• Change in the way things taste
• Dry eyes, blurred eye sight
• Dry skin, itching
• Feeling dizzy
• Headache
• Chest pain
• Confusion, depression, nervousness

Uncommon side effects (affects less than 1 in 100 people):
• Abdominal discomfort
• Frequent bowel movements
• Hoarseness, throat irritation
• Flushing, hot flush
• Chest discomfort
• Mucosal dryness (multiple sites)
• Loss of appetite

The following side effects have been reported with the use of DITROPAN XL®:
• Central nervous system (CNS) effects, their symptoms include anxiety, agitation, difficulty remembering
• Difficulty getting or keeping an erection
• Skin rash, swelling of the skin, hives
• Falling

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and seek immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common High Blood Pressure: headache, vision problems, dizziness, shortness of breath</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td>Uncommon Seeing or hearing things that are not really there</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Feeling agitated, behaving irrationally and thinking abnormally</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Rare Convulsions</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Very Rare Fast or uneven heartbeat</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>
Angioedema and Severe Allergic Reactions:
swelling of the face, eyes, or tongue, difficulty swallowing, wheezing, hives and generalized itching, rash, fever, abdominal cramps, chest discomfort or tightness, difficulty breathing, unconsciousness

Glaucoma:
increased pressure in your eyes, eye pain

This is not a complete list of side effects. For any unexpected effects while taking DITROPAN XL®, contact your doctor or pharmacist.

HOW TO STORE IT

Store between 15 and 30°C. Protect from moisture and humidity. Keep out of reach and sight of children.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
    Health Canada
    Postal Locator 1908C
    Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect® Canada Web site at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full Product Monograph prepared for health professionals can be found at:
http://www.janssen.com/canada
or by contacting the sponsor, Janssen Inc., at:
1-800-567-3331 or 1-800-387-8781.

This leaflet was prepared by Janssen Inc.
Toronto, Ontario M3C 1L9

Last revised: August 2018

All trademarks used under license.